Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06313567
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-03-10
Brief Title:
Metronomic Capecitabine in Stage III Gastric Cancer
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
Metronomic Capecitabine as Adjuvant Therapy in Stage III Gastric Cancer a Multicentre Open-label Parallel-group Randomised Controlled Phase 3 Trial
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out whether treatment with metronomic capecitabine will improve the survival of gastric cancer patients with stage III who had received standard treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None